Stem Cell Therapy for Infertility Market Report 2026

The stem cell therapy for infertility market size has grown rapidly in recent years. It will grow from $1.87 billion in 2025 to $2.18 billion in 2026 at a compound annual growth rate (CAGR) of 16.6%. The growth in the historic period can be attributed to increasing prevalence of infertility conditions, growth of fertility clinics globally, advancements in reproductive biology research, rising demand for alternative infertility treatments, expansion of assisted reproductive procedures.

The stem cell therapy for infertility market size is expected to see rapid growth in the next few years. It will grow to $3.99 billion in 2030 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to increasing clinical validation of stem cell infertility treatments, rising investments in reproductive regenerative medicine, growing acceptance of personalized fertility solutions, expansion of clinical trials in reproductive health, increasing collaboration between fertility clinics and research institutions. Major trends in the forecast period include increasing focus on ovarian and testicular regeneration therapies, rising use of autologous stem cell treatments, growing integration with assisted reproductive technologies, expansion of personalized fertility treatment protocols, enhanced clinical research in reproductive regeneration.

The rising cases of infertility are expected to significantly drive the growth of the stem cell therapy for infertility market. Infertility is defined as the inability of a couple to conceive after 12 months or more of regular unprotected sexual intercourse. The increasing prevalence of infertility is largely linked to delayed childbearing, as many individuals choose to have children later in life, resulting in reduced fertility due to the natural decline in reproductive potential with age, particularly among women. Stem cell therapy for infertility offers promising solutions by regenerating damaged reproductive tissues, improving ovarian and testicular function, and enhancing the chances of conception. For instance, in April 2023, the World Health Organization (WHO) reported that infertility affects approximately 17.5% of the adult population globally, or about 1 in 6 people, highlighting the growing need to expand access to affordable and high-quality fertility care. Therefore, the rising prevalence of infertility is expected to drive the expansion of the stem cell therapy for infertility market.

Major companies in this market are focusing on advancements in stem cell technologies, such as induced pluripotent stem cells (iPSCs), to develop personalized regenerative treatments, improve patient-specific outcomes, and broaden the range of treatable reproductive conditions. Induced pluripotent stem cells are adult somatic cells genetically reprogrammed to an embryonic-like pluripotent state, enabling them to differentiate into nearly any cell type in the body. For instance, in January 2025, Gameto Inc., a U.S.-based biotechnology company, initiated a pivotal Phase III clinical trial for its iPSC-derived fertility therapy, Fertilo, after receiving Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). The trial, conducted across approximately 15 sites in the U.S., evaluates egg maturation outside the body using engineered ovarian support cells, potentially shortening IVF cycles and reducing hormonal stimulation by up to 80%. If successful, this would mark the first late-stage clinical program for an in-vitro matured egg therapy derived from iPSCs for treating infertility.

In October 2023, REPROCELL Inc., a Japan-based biotechnology company, acquired Gameto Inc. for an undisclosed amount. Through this acquisition, REPROCELL aims to strengthen its position in the fertility and regenerative medicine sector by integrating Gameto’s advanced iPSC-based fertility technologies to accelerate the development of innovative infertility treatments. Gameto Inc. is a U.S.-based biotechnology company specializing in stem cell therapies for infertility.

Major companies operating in the stem cell therapy for infertility market are PlacidWay LLC, New Life India Fertility Clinic Private Limited, Jeevan Mithra Fertility Centre Private Limited, Equipo IVI S.L., Hope Fertility & Stem Cell Centre Pvt. Ltd., Bioscience Institute SpA, Advancells Dermaceuticals Private Limited, GIOSTAR INDIA PRIVATE LIMITED, Shree IVF Clinic Private Limited, Stem Cells Care (india) Private Limited, GenCell Ltd., StemRx BioScience Solutions Private Limited., Kiran Infertility Centre Private Limited, R3 Stem Cell LLC., Bavishi Fertility Institute Private Limited, Seragen Biotherapeutics Private Limited, Esha IVF Fertility Centre Private Limited, Embryonic Tissue Center EmCell, InoCells B.V., Vega Stem Cell Clinic Co. Ltd.

North America was the largest region in the stem cell therapy for infertility market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stem cell therapy for infertility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell therapy for infertility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the stem cell therapy for infertility market by increasing costs of imported laboratory reagents, cell processing equipment, cryopreservation systems, and diagnostic tools. Fertility clinics and research centers in North America and Europe are most affected due to reliance on specialized imported technologies, while Asia-Pacific faces higher treatment setup costs. These tariffs are raising procedural expenses and limiting access to advanced therapies. However, they are also encouraging domestic sourcing of fertility lab equipment, regional clinical partnerships, and localized development of reproductive stem cell technologies.

The stem cell therapy for infertility market research report is one of a series of new reports that provides stem cell therapy for infertility market statistics, including stem cell therapy for infertility industry global market size, regional shares, competitors with a stem cell therapy for infertility market share, detailed stem cell therapy for infertility market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell therapy for infertility industry. This stem cell therapy for infertility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stem cell therapy for infertility is an advanced regenerative treatment that uses stem cells to restore or enhance the function of reproductive tissues and organs in both men and women. It aims to repair damaged ovarian, testicular, or endometrial tissues, improve gamete quality, and support hormonal balance.

The main components of stem cell therapy for infertility include male infertility treatment and female infertility treatment. Stem cell therapy for male infertility uses stem cells to restore or enhance sperm production and overall reproductive function in men with impaired fertility. Treatment types include autologous stem cell therapy, allogeneic stem cell therapy, and combination therapies. Stem cells are sourced from embryonic stem cells, adult stem cells, and induced pluripotent stem cells. Applications include ovarian insufficiency, uterine infertility, and genetic reproductive disorders. End users include hospitals, specialty clinics, and research institutes.

The stem cell therapy for infertility market includes revenues earned by providing services such as fertility restoration therapy services, clinical research support services, biobanking of stem cell services, allogeneic stem cell transplantation services, and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.